Breyanzi Manufacturer is Bristol Myers Squibb (BMS)

Breyanzi Manufacturer is Bristol Myers Squibb (BMS)

Breyanzi is developed and produced by the global biopharmaceutical company manufacturer is Bristol Myers Squibb (BMS).

Tracing the history of the global biopharmaceutical giant Bristol Myers Squibb (BMS), every step it has taken has been in sync with the rhythm of the times. From ether to penicillin, it served as a major military supplier during the Civil War and World War II. In 1929, BMS successfully listed on the NYSE, just before the burst of the global financial bubble. In the late 1960s, it caught the tail end of the “baby boom” by acquiring infant formula manufacturer Mead Johnson.

The company’s development has witnessed the rise and prosperity of the American economy, traversing through its various economic cycles of ups and downs.

Bristol Myers Squibb: The Fruit of a Powerful Merger

Bristol Myers Squibb was formed from the merger of Bristol-Myers and Squibb in 1989. Subsequently, in 2019, BMS acquired Celgene, shaping its current scale.

The history of BMS can be traced back to 1852, when Dr. Squibb, born in the United States, developed a method for producing ether and shared his discovery with the pharmaceutical community. The government later encouraged him to establish his own company.

In 1858, Dr. Squibb started his pharmaceutical business in Brooklyn, New York. In 1879, he submitted a proposed law to the New York State Medical Society “to prevent the adulteration of food and drugs and to establish a National Board of Health,” known as the Squibb Law. This law later became the basis for the Federal Pure Food and Drug Act signed by President Theodore Roosevelt (not the one elected in 1933) in 1906.

In 1887, William Bristol and John Myers invested $5,000 to acquire the nearly bankrupt Clinton Pharmaceutical Company, later known as Bristol-Myers. The company’s name was derived from the surnames of William Bristol and John Myers. Promising not to sell “quack remedies,” the two quickly turned around the plight of Clinton Pharmaceutical Company. The following year, Clinton Pharmaceutical Company promoted 1,800 products in its first product catalog, including “gelatin-coated pills and granules, compressed tablets, triple salts, hypodermic tablets, elixirs, wines, and syrups.”

In 1892, Dr. Squibb and his son established a father-son company with assets worth $1.5 million.

In 1895, Bristol-Myers launched its first hit product, Sal Hepatica, sold as a tonic and laxative, known as “the poor man’s spa,” mimicking the taste and effects of the natural mineral waters at Bohemian spas. Within a decade, its annual sales rose to $500,000, and it remained Bristol-Myers’ leading product until 1974.

In 1901, Bristol-Myers introduced Ipana toothpaste, which could prevent tooth decay and gum disease.

In 1902, Squibb established the first quality control laboratory. Soon, it had nearly 100 employees and produced over 800 preparations.

In 1914, Squibb’s biological laboratories produced antibodies, serums, and vaccines, and were a major supplier of ether during World War I.

In 1917, Squibb pioneered the standardization of digitalis, an early treatment for heart disease.

In 1919, Squibb’s production lines expanded significantly, with its product range growing to 2,382 items sold in 6,547 packages, including newly introduced veterinary products. The company expanded westward, opening a distribution center in Chicago and an export department in Brooklyn, establishing its leadership in international trade.

In the early decades of the 20th century, Squibb produced vaccines to prevent common diseases such as diphtheria, tuberculosis, tetanus, and typhoid fever. By 1921, Squibb produced over-the-counter household remedies like bicarbonate of soda, castor oil, milk of magnesia, and salts.

In 1929, Bristol-Myers went public on the NYSE, just before the burst of the global financial bubble.

In 1939, Squibb researchers developed a new method for preparing curare and provided purified tubocurarine chloride samples to clinical researchers, finding that purified curare could be used as a muscle relaxant.

In 1943, Bristol-Myers acquired Cheplin Laboratories in New York, enabling large-scale penicillin production during World War II, marking the company’s entry into ethical drug development. Meanwhile, in 1944, Squibb opened the world’s largest penicillin production plant in New Jersey.

In 1948, Bristol-Myers introduced long-acting injectable penicillin Flo-Cillin 96 and buffered solutions.

In 1956, Bristol-Myers entered cancer drug development, collaborating with the Japanese Microbial Chemistry Research Foundation to develop antibiotics.

In 1959, Bristol-Myers acquired hair dye company Clairol.

In 1967, Bristol-Myers acquired infant formula and other nutritional product manufacturer Mead Johnson, whose drugs included the early anti-cancer drugs megestrol acetate (Megace) and cyclophosphamide. That same year, Squibb developed the first anti-cancer product, hydroxyurea (Hydrea).

In 1972, Bristol-Myers established a film company, producing several films, including “The Stepford Wives” and “The Taking of Pelham One Two Three,” but exited the film business two years later.

In 1973, Bristol-Myers introduced mutamycin for the treatment of bone cancer, stomach cancer, and pancreatic tumors.

In 1974, Bristol-Myers introduced the cancer chemotherapy drug Blenoxane (bleomycin sulfate) for the treatment of squamous cell carcinoma, head and neck cancer, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma.

In 1975, Squibb developed the first ACE inhibitor, CAPOTEN (captopril), for hypertension and heart failure.

In 1978, Squibb established ConvaTec, selling ostomy and wound care products.

In 1979, PLATINOL (cisplatin) became the first platinum-based anti-cancer drug for the treatment of testicular cancer.

In 1983, the FDA approved Bristol-Myers’ VePesid (etoposide) for testicular cancer patients unresponsive to standard chemotherapy.

In 1986, Celgene Corporation was founded. That same year, BUSPAR, discovered by Bristol-Myers neuroscience researchers, was approved for the treatment of generalized anxiety disorder.

In 1989, Squibb and Bristol-Myers merged to become a global leader in the healthcare industry. The merged Bristol-Myers Squibb became the second-largest pharmaceutical company at the time. The new company’s first batch of products included PARAPLATIN, approved for the treatment of recurrent ovarian cancer.

From its creation history, it is evident that Squibb focused on research and development, while the trendy Bristol-Myers was always chasing trends and actively participating in high-traffic areas, acquiring companies whenever necessary.

After the merger, Bristol-Myers Squibb continued Squibb’s research and development spirit but also maintained Bristol-Myers’ “shopping” enthusiasm.

In 2001, Bristol-Myers Squibb acquired DuPont Pharmaceuticals, strengthening its HIV and cardiovascular businesses while adding medical imaging and gaining the drugs efavirenz (Sustiva) and warfarin (COUMADIN).

Since 2005, Bristol-Myers Squibb has acquired biotechnology companies and partners, including Medarex, greatly expanding its oncology and immunology product lines, with the acquisition completed in 2009.

In 2019, Bristol-Myers Squibb acquired Celgene.

In 2020, Bristol-Myers Squibb acquired MyoKardia for $13.1 billion, strengthening its leading cardiovascular franchise, and acquired Forbius, adding its leading TGF-β asset to its portfolio.

In 2022, Bristol-Myers Squibb acquired clinical-stage biotech Turning Point for $4.1 billion in cash, further expanding its precision oncology and cardiovascular product portfolios.

From its development, it is evident that Bristol-Myers Squibb’s history is closely intertwined with that of the United States. Although its business spans globally, the U.S. market’s share for the company has continued to increase, from 49.44% in 2015 to 68.95%.

Assuming you are a professional Chinese-English medical translator, particularly proficient in medical knowledge and Chinese-English translation, capable of accurately translating medical terminology, you are now required to use your professional knowledge to accurately translate the above article into English. It is essential that medical terms are translated with precision, and the semantics are clear.

Content Source:赛富科技